LPL Financial LLC Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

LPL Financial LLC boosted its position in Zimmer Biomet Holdings, Inc. ( NYSE:ZBH – Free Report ) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission.

The fund owned 99,721 shares of the medical equipment provider’s stock after acquiring an additional 10,122 shares during the period. LPL Financial LLC’s holdings in Zimmer Biomet were worth $10,534,000 at the end of the most recent reporting period. A number of other hedge funds have also recently modified their holdings of ZBH.



CKW Financial Group increased its holdings in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the period.

Romano Brothers AND Company increased its stake in shares of Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares during the period.

Dorsey & Whitney Trust CO LLC raised its holdings in shares of Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after acquiring an additional 102 shares in the last quarter.

M&T Bank Corp lifted its stake in Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after acquiring an additional 108 shares during the period.

Finally, Dakota Wealth Management boosted its holdings in Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares in the last quarter.

Hedge funds and other institutional investors own 88.89% of the company’s stock. Analysts Set New Price Targets Several research analysts have commented on the stock.

Truist Financial restated a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th.

Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th.

JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.

00 in a research report on Tuesday, December 17th. JMP Securities restated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th.

Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.

com, the stock currently has an average rating of “Hold” and an average target price of $124.15. Insider Buying and Selling In related news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th.

The shares were sold at an average price of $104.40, for a total value of $150,649.20.

Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.

13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link . 0.

70% of the stock is currently owned by corporate insiders. Zimmer Biomet Trading Up 0.2 % Zimmer Biomet stock opened at $112.

72 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $97.

69 and a one year high of $130.89. The business’s fifty day moving average is $107.

38 and its 200 day moving average is $107.21. The stock has a market capitalization of $22.

44 billion, a PE ratio of 25.33, a price-to-earnings-growth ratio of 1.95 and a beta of 1.

04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.

91 and a quick ratio of 0.99. Zimmer Biomet ( NYSE:ZBH – Get Free Report ) last announced its quarterly earnings results on Thursday, February 6th.

The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.

01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.

99%. During the same quarter in the prior year, the firm posted $2.20 EPS.

On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend.

The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.

85%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

About Zimmer Biomet ( Free Report ) Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.

T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. Read More Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. ( NYSE:ZBH – Free Report ). Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.

com's FREE daily email newsletter ..